Australian & New Zealand Childrens Haematology/Oncology Group
Study Title
Phase I/II multicenter study to assess efficacy and safety of ribociclib (LEE011) in combination with topotecan and temozolomide (TOTEM) in pediatric patients with relapsed or refractory neuroblastoma and other solid tumors
Protocol ID
CLEE011Q12101
Disease (Sub Disease)
Neuroblastoma
Diagnosis Stage
Relapse/refractory
Location
NSW
Sponsor
Novartis Pharmaceuticals
Collaborators
Innovative Therapies For Children with Cancer Consortium
Links
Trial Status
Open
Sites
Sydney Children's Hospital
Study Type
Interventional
Phase
Phase 1/2
Age Eligibility
12 months to 21 years
International registry ID's
NCT05429502
| Study Title | Phase I/II multicenter study to assess efficacy and safety of ribociclib (LEE011) in combination with topotecan and temozolomide (TOTEM) in pediatric patients with relapsed or refractory neuroblastoma and other solid tumors |
|---|---|
| Protocol ID | CLEE011Q12101 |
| Disease (Sub Disease) | Neuroblastoma |
| Diagnosis Stage | Relapse/refractory |
| Location | NSW |
| Sponsor | Novartis Pharmaceuticals/ |
| Collaborators | Innovative Therapies For Children with Cancer Consortium/ |
| Links | https://clinicaltrials.gov/study/NCT05429502 |
| Trial Status | Open |
| Trial Open Date | 27/12/2022 |
| Sites | Sydney Children's Hospital |
| Study Type | Interventional |
| Phase | Phase 1/2 |
| Age Eligibility | 12 months to 21 years |
| International registry ID's | NCT05429502 |